Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Receivables: 2018-2025

Historic Change in Receivables for Bicycle Therapeutics (BCYC) over the last 5 years, with Mar 2025 value amounting to $133,000.

  • Bicycle Therapeutics' Change in Receivables was N/A to $133,000 in Q1 2025 from the same period last year, while for Mar 2025 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of -$2.5 million for FY2023, which is 251.25% down from last year.
  • As of Q1 2025, Bicycle Therapeutics' Change in Receivables stood at $133,000, which was down 99.73% from $49.9 million recorded in Q3 2023.
  • Over the past 5 years, Bicycle Therapeutics' Change in Receivables peaked at $49.9 million during Q3 2023, and registered a low of -$49.8 million during Q2 2023.
  • In the last 2 years, Bicycle Therapeutics' Change in Receivables had a median value of -$1.2 million in 2023 and averaged -$587,250.
  • The largest annual percentage gain for Bicycle Therapeutics' Change in Receivables in the last 5 years was 614.50% (2023), contrasted with its biggest fall of 582.14% (2023).
  • Bicycle Therapeutics' Change in Receivables (Quarterly) stood at $1.0 million in 2021, then spiked by 98.70% to $2.0 million in 2022, then surged by 614.50% to $49.9 million in 2023, then reached $133,000 in 2025.
  • Its Change in Receivables stands at $133,000 for Q1 2025, versus $49.9 million for Q3 2023 and -$49.8 million for Q2 2023.